GlassScriptPhysician profile
Jong Geol Park
NPI 1386173870
$11,951.66
in general payments reported to CMS, 2019-2025
13 companies · $8,445 in 2025
The $8,445 reported for 2025 was more than what 90% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,627 · 2020: $123 · 2021: $163 · 2022: $1,165 · 2023: $362 · 2024: $66.09 · 2025: $8,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,732 · Consulting Fee: $2,556 · Food and Beverage: $586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,731.64 |
| Consulting Fee | $2,555.58 |
| Food and Beverage | $586.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hoffmann-La Roche Limited | $8,397.66 | 2025 | Vabysmo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,510.38 | 2019 | |
| Dutch Ophthalmic, USA | $515.49 | 2022 | |
| Abbvie INC. | $337.96 | 2022-2025 | |
| Genentech USA, INC. | $248.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $244.54 | 2020-2021 | |
| Eyepoint US, INC. | $147.96 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $134.80 | 2023 | Xipere, Visudyne |
| Alimera Sciences, INC. | $133.48 | 2023 | Iluvien |
| Apellis Pharmaceuticals, INC. | $124.00 | 2022 | |
| Aerie Pharmaceuticals, INC. | $116.95 | 2019 | |
| Coherus Oncology, INC. | $22.17 | 2023 | |
| Alcon Vision LLC | $18.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jong Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.